Скачать или смотреть Big pharma just made $3.4 BILLION, so why is everyone laid off?

Biotech companies just raised $3.4 BILLION in two weeks, so why is everyone getting fired? In 2026, the industry is rich, but the job market is a graveyard. Here is the paradox explained.

----------------------------------------------------------------------------

This week in biopharma, we’re breaking down the wack economics of how big pharma can prosper while letting people go. While Amgen, Eli Lilly, and Aktis are cutting massive checks for new tech, they aren't hiring new people. We explore the specific "Guided Missile" technologies (ADCs and T-Cell Engagers) that are attracting all the capital, and why the FDA has suddenly entered its Villain Era with unpredictable rejections.

If you are working in biotech, investing in pharma, or just like seeing cancer cells explode, this breakdown is for you.
----------------------------------------------------------------------------
Timestamps:
0:00 - Intro
0:30 - Big pharma spending in 2026
3:10 - 2025 layoffs in pharma
4:22 - Innovation at the cost of jobs: precision medicine
8:02 - Matty Cpeed Round
9:08 - FDA disagrees with top experts
----------------------------------------------------------------------------
References:
• VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026: https://www.biospace.com/business/vc-...
• Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs https://www.biopharmadive.com/news/li...
• Amgen Makes up to $840M Cancer Play With Dark Blue Takeover https://www.biospace.com/business/amg...
• Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact https://www.biospace.com/deals/gilead...
• AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug https://www.biospace.com/deals/abbvie...
• Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic https://www.biospace.com/business/cor...
• Aktis raises $318M in 2026’s first biotech IPO https://www.biopharmadive.com/news/ak...
• Roche Spends $570M on Another ADC Agreement With China’s MediLink https://www.biospace.com/deals/roche-...
• Biopharmas Axed 47% More Employees Year Over Year https://www.biospace.com/job-trends/b...
• Small molecule that stops cancer-specific proteins from being utilized https://dark-blue-therapeutics-d2-ce1...
• Acute myeloid leukemia: https://phoresearchghent.org/acute-my...
• Ultra pH sensitive polymeric micelles https://www.onconano.com/technology-o...
• GSK, Ionis claim study success for RNA-based hepatitis B drug
https://www.biopharmadive.com/news/gs...
• J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark https://www.biospace.com/drug-develop...
• FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices https://www.biospace.com/fda/fda-reje...
• FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025 https://www.biospace.com/fda/fda-went...
• FDA Expert Panels Lack Balance in Pursuit of ‘Gold Standard Science’ https://www.biospace.com/fda/fda-expe...

#Biotech #PharmaNews #ScienceExplained #BiomedicalEngineering #CancerResearch #ADCs #MattyC